NCT00813293View on ClinicalTrials.gov

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Hepatocellular Cancer
Interventions
DRUG

Sorafenib

PROCEDURE

radiofrequency ablation

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Onyx Therapeutics, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Beth Israel Deaconess Medical Center

OTHER